Baidu
map

Int J Cardiol:房颤患者不合理抗凝的发生率和预测因素

2017-11-01 吴星 环球医学

2017年12月,发表在《Int J Cardiol》上的一项回顾性研究,旨在确定CHA2DS2-VASc评分为0的房颤患者不合理抗凝治疗的真实发生率和预测因素。研究结果显示:12%的CHA2DS2-VASc评分为0的房颤患者的抗凝处方不合理,且不必要抗凝的独立预测因素为年龄、体重指数、当前不使用阿司匹林和持续性房颤。

2017年12月,发表在《Int J Cardiol》上的一项回顾性研究,旨在确定CHA2DS2-VASc评分为0的房颤患者不合理抗凝治疗的真实发生率和预测因素。研究结果显示:12%的CHA2DS2-VASc评分为0的房颤患者的抗凝处方不合理,且不必要抗凝的独立预测因素为年龄、体重指数、当前不使用阿司匹林和持续性房颤。

背景:既往研究表明,CHA2DS2-VASc评分≥2的房颤患者抗凝治疗的使用不足,然而,CHA2DS2-VASc评分为0的房颤患者不合理抗凝的使用情况几乎没有数据。因此,研究人员旨在确定CHA2DS2-VASc评分为0的房颤患者不合理抗凝治疗的真实发生率和预测因素。

方法:研究人员对医院2009年1月~2016年1月所有CHA2DS2-VASc评分为0的房颤患者进行了回顾性病例审查。人口统计学和临床数据从电子病历记录中收集。研究人员使用多变量逻辑回归分析确定不合理抗凝治疗的独立临床预测因素。

结果:共鉴别出512例CHA2DS2-VASc评分为0并确诊为房颤的患者。开具抗凝处方的137例患者中,在评估了华法林或新型抗凝治疗的其他适应证后,64例被认为抗凝治疗不合理。与不合理抗凝处方相关的独立变量为年龄(OR,1.07;95% CI,1.03~1.10)、体重指数(1.06;1.01~1.10)、当前不使用阿司匹林(13.50;6.00~30.54)、持续性房颤(2.34;1.11~4.94)。

结论:研究表明,12%的CHA2DS2-VASc评分为0的房颤患者的抗凝处方不合理。不必要抗凝的独立预测因素为年龄、体重指数、当前不使用阿司匹林和持续性房颤。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781815, encodeId=686f1e81815fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Dec 06 10:32:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826392, encodeId=2cdb1826392d5, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Nov 24 09:32:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264262, encodeId=3a341264262aa, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614414, encodeId=95b31614414e6, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781815, encodeId=686f1e81815fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Dec 06 10:32:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826392, encodeId=2cdb1826392d5, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Nov 24 09:32:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264262, encodeId=3a341264262aa, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614414, encodeId=95b31614414e6, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781815, encodeId=686f1e81815fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Dec 06 10:32:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826392, encodeId=2cdb1826392d5, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Nov 24 09:32:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264262, encodeId=3a341264262aa, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614414, encodeId=95b31614414e6, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781815, encodeId=686f1e81815fb, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Wed Dec 06 10:32:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1826392, encodeId=2cdb1826392d5, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Nov 24 09:32:00 CST 2017, time=2017-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1264262, encodeId=3a341264262aa, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614414, encodeId=95b31614414e6, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Fri Nov 03 07:32:00 CST 2017, time=2017-11-03, status=1, ipAttribution=)]

相关资讯

围术期疼痛的全程管理病例分享_高龄、房颤患者腹腔镜Dixon术麻醉镇痛管理病例

患者,男,74岁,体重48 kg,本次主因“ 直肠癌4 程新辅助化疗后3 周”入院,拟行“腹腔镜下直肠癌前切除(Dixon)术”。

Eur Heart J:以生物标志物为基础的风险评分可预测房颤患者死亡!

ABC死亡风险评分在AF患者预测死亡风险上表现良好,可能有助于AF患者的整体风险评估。

Eur Heart J:房颤患者口服抗凝药可减少痴呆!

由此可见,没有接受口服抗凝治疗的房颤患者发生痴呆的风险更高。这表明房颤患者早期开始抗凝治疗在保持认知功能上很有价值。

JAHA:口服抗凝血药相比华法林更能降低房颤患者卒中风险

对于房颤患者,直接口服抗凝血药物(DOACs)在卒中预防方面相比于华法林是非劣效等级。本研究的目的旨在根据抗凝血药物的类型和等级评估房颤患者卒中和死亡发生的风险。本次人群队列研究是基于加拿大亚伯达地区的人群健康数据库,主要终点事件是卒中和死亡。最终,共纳入34965名房颤患者(男性占56%,平均年龄为73岁),相比于华法林,接受DOAC治疗患者的卒中和死亡发生风险更低(HR:0.90; 95% C

JACC综述:有房颤的人胖点好?别想美事儿了!

近期,发表在JACC上的一篇综述,通过梳理大量研究很细致地探究了当前两大流行疾病肥胖和房颤之间的“纠葛”,并指出“肥胖悖论”机制不是很明确,管理体重是王道。 所谓的“肥胖悖论”,就是近来一些研究发现了一种现象:超重或肥胖的房颤患者,远期全因死亡率要比正常体重房颤患者更低。比如ORBIT-AF注册研究就显示,I级肥胖患者的全因死亡风险就比正常体重指数(BMI)房颤者降低了35%。 

Int J Cardiol:他汀能改善房颤患者结局

2017年12月,发表在《Int J Cardiol》上的一项研究,考察了他汀的使用对房颤(AF)患者死亡风险的影响。研究结果表明:AF患者使用他汀与结局改善相关,与1年随访时较低的全因死亡风险独立相关。

Baidu
map
Baidu
map
Baidu
map